Abstract
In Brief Mucormycosis infection is an often fatal complication of chronic immunosuppressive therapy in patients with hematological malignancies. This risk can be further heightened in patients who are on chronic suppressive therapy with voriconazole. We review a case of an immunocompromised patient on chronic suppressive voriconazole therapy who developed severe pulmonary mucormycosis infection. Long-term treatment with voriconazole can further increase the risk of pulmonary mucormycosis in immune-compromised patients. This case illustrates the heightened risk of pulmonary mucormycosis associated with chronic suppression therapy with voriconazole in a patient with recurrent acute lymphoblastic leukemia.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
